louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06479044: Applying Herrmann's Brain Quadrant Model to Learning Styles in Anesthesiology Residents
Official title: Application Of Herrmann's Brain Quadrant Model and Its Relationship With Learning Styles in Anesthesiology Residents
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Learning Problem
Keywords: Residency
Learning
Herrmann´s Model
Medical Knowledge
Cognitive Function
Lead sponsor: Instituto Mexicano del Seguro Social
Sponsor class: OTHER_GOV
First posted: 2024-06-27
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Physicians between 27 and 32 years of age of both genders

Brief summary: the ability to learn and adapt to clinical demands is essential in the training of residents. The Herrmann Brain Model categorizes thinking styles based on the preference for utilizing brain quadrants, serving as an applied tool for residents to assess their learning preferences.

Detailed description: This study delineates the learning styles according to Herrmann's brain quadrant model among anesthesiology residents at the National Western Specialty Hospital, Mexican Social Security Institute. Cross-sectional descriptive study; the Herrmann Brain Dominance Test was administered to anesthesiology residents. Each brain quadrant embodies distinct characteristics, thinking patterns, and approaches to knowledge acquisition. The test comprises 120 multiple-choice items on academic, daily, and professional scenarios. The quadrants are described as follows: LC "Scientific Expert," LL "Organizer-Introvert," RC "Interpersonal Strategist," RL "Imaginative Communicator."

Eligibility criteria: Inclusion Criteria:

* Anesthesiology residents of the National Western Specialty Hospital, Mexican Social Security Institute

Exclusion Criteria:

* Residents of other specialties of the National Western Specialty Hospital, Mexican Social Security Institute

Primary outcomes:
measure: Quadrant dominance
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Guadalajara
country: Mexico
facility: National Western Speciality Hospital, Mexican Social Security Institute
state: Jalisco
Study officials:
References:
Clinical trial NCT06917144: Refractory Chronic Cluster Headache: Exploring the Potential of Repetitive Transcranial Magnetic Stimulation
Official title: Evaluating Repetitive Transcranial Magnetic Stimulation for Refractory Chronic Cluster Headache Prevention: Insights From a Randomised Crossover Pilot Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Refractory Chronic Cluster Headache
Lead sponsor: Hospital Universitario La Paz
Sponsor class: OTHER
First posted: 2025-04-08
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The goal of this clinical trial is to learn if drug ABC works to treat severe asthma in adults. It will also learn about the safety of drug ABC. The main questions it aims to answer are:

Does Transcranial Magnetic Stimulation lower the number of attacks per week in patients with refractory cluster headache ?

Researchers will compare transcranial magnetic stimlation to a sham stimulation (a look-alike stimulation) to see if it works to prevent attacks of cluster headache.

Participants will:

Recieve stimulation for 10 minutes for 10 consecutive working days in 2 periods of time, separated by a 1 month washout period.

Visit the clinic for each treatment day. Keep a diary of their symptoms and the number of times they use a rescue medication


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* Diagnosed with Chronic Cluster Headache (CCH) based on the International Classification of Headache Disorders 3rd Edition
* Diagnosed with refractory CCH based on the European Headache Federation criteria of 2014.

Exclusion Criteria:

* History of epilepsy.
* Concomitant diagnosis of any other headache (if the patient was unable to differentiate between them).
* Carriers of any electronic device, or any additional contraindication for Transcranial Magnetic Stimulation, such as pregnancy.

Primary outcomes:
measure: Reduction in number of attacks per week
timeFrame: From enrollment to the end to follow up period, at 3 months after last treatment period (week 8)
Secondary outcomes:
measure: Assessing the reduction in symptomatic medication use.
timeFrame: From enrollment to the end of follow up period, at 3 months after second treatment period (week 8)
measure: To assess the reduction in intensity of cluster headache attacks
timeFrame: From enrollment to the end of follow up period, at 3 months after second treatment period (week 8)
measure: To assess the change in duration in cluster headache attacks
timeFrame: From enrollment to the end of follow up period, at 3 months after second treatment period (week 8)
measure: To assess the tolerability to treatment
timeFrame: From enrollment to the end of follow up period, at 3 months after second treatment period (week 8)
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Hospital Universitario La Paz
Study officials:
References:
Clinical trial NCT01840644: Validity and Reliability of Perceived Exertion Rating Scale in Children With Brain Damage
Official title: Validity and Reliability of Perceived Exertion Rating Scale in Children With Traumatic Brain Injury, Cerebral Palsy and Typically Developed
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Traumatic Brain Injury
Cerebral Palsy
Lead sponsor: Alyn Pediatric & Adolescent Rehabilitation Hospital
Sponsor class: OTHER
First posted: 2013-04-26
Enrollment: 25
Sex: ALL
Minimum age (years): 7
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children post severe TBI Children with CP TD control

Brief summary: The purpose of this study is to examine the reliability and validity of the rating of perceived exertion scale in children post severe traumatic brain injury during treadmill exercise.

Detailed description: walking on a treadmill twice- one weeks interval five intensity level in each session

Eligibility criteria: Inclusion Criteria:

* Children post severe closed head injury (Glasgow Coma Scale \[GCS\] score at admission to emergency room of ≤8, at least one year post trauma
* Ages 7 to 12 years
* (3) independent ambulation (foot orthoses permitted).
* Children with Cerebral palsy, GMFCS 1 or 2, ages 7 to 12 years. Typically developed controls.

Exclusion criteria:

* Cannot understand simple instructions

Primary outcomes:
measure: OMNI scale, a pictorial perceived extortion scale for children
timeFrame: three meetings once a week.
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Alyn Children's Rehabilitation Hospital
Study officials:
affiliation: Alyn rehabilitation center
name: Michal Katz, Phd
role: STUDY_DIRECTOR
References:
Clinical trial NCT04484844: Clinical Evaluation of Efficacy of Shield Force Plus Varnish VS Sodium Fluoride on Dentin Hypersensitivity
Official title: Clinical Evaluation of Efficacy of Shield Force Plus Varnish Versus Sodium Fluoride on Cervical Dentin Hypersensitivity on Adult Patients: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Dentin Hypersensitivity
Dentin Desensitizing Agents
Keywords: Dentin hypersensitivity
Dentin sensitivity
Shield force plus
Dentin Desensitizing Agents
sodium fluoride varnish
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-07-24
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the study to compare the clinical effectiveness of Shield Force Plus (SFP) versus sodium fluoride varnish in the management of hypersensitivity of cervical dentin in adult patients for 8weeks.


Eligibility criteria: Inclusion Criteria:

* Patients with good oral hygiene.
* The age range of 18-65 years.
* Patients from both gender.
* Patients suffering from pain due to dentin hypersensitivity.
* Patients with sound first upper molars.

Exclusion Criteria:

* Patients with teeth exhibiting mobility (grade 2 or 3).
* Patients with constant use of analgesic, carious lesions, fractured teeth, defective restorations or prosthesis.
* Patients with orthodontics appliance.
* Patients with allergy sufferers with any of the materials will be used in the study as shield force plus and sodium fluoride.
* Patients with carious, crowned upper first molars.

Primary outcomes:
measure: Dentin Hypersensitivity
timeFrame: Pre-intervention
measure: Dentin Hypersensitivity
timeFrame: 2 min
measure: Dentin Hypersensitivity
timeFrame: 1 week
measure: Dentin Hypersensitivity
timeFrame: 4 weeks
measure: Dentin Hypersensitivity
timeFrame: 8 weeks
Secondary outcomes:
measure: Dentinal Tubule Occlusion
timeFrame: Pre-intervention
measure: Dentinal Tubule Occlusion
timeFrame: 8 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01203540: Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients
Official title: Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Allergic Conjunctivitis
Lead sponsor: Laboratoires Thea
Sponsor class: INDUSTRY
Collaborators: name: Samil Pharmaceutical Co., Ltd.
First posted: 2010-09-16
Enrollment: 21
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Multicentre, Double blind, Randomized, Comparative Study(comparing N-acetyl-aspartyl-glutamic acid(NAAGA) in Abak preservative free device versus SALINE in Abak preservative free device.

Evaluation of the effects and safety of NAABAK® through inflammation markers and symptoms in patients with allergic conjunctivitis and dry eye syndrome after 3 months treatment.

The patients will attend 4 visits.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 20 years old
* Patients with dry eye syndrome in allergic conjunctivitis

Exclusion Criteria:

* Severe dry eye syndrome
* Severe ocular pathology

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
city: Seoul
country: Korea, Republic of
facility: Seoul National University Boramae Medical Center
Study officials:
References:
Clinical trial NCT01598740: Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease
Official title: A Phase 1, Open-label, Randomized, Crossover Study to Assess the Safety, Tolerability, and Efficacy of CLP With and Without Spironolactone in Adults With Heart Failure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Heart Failure
Lead sponsor: Sorbent Therapeutics
Sponsor class: INDUSTRY
First posted: 2012-05-15
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the effects of CLP, with and without spironolactone, on serum, urine, and fecal contents in heart failure patients with chronic kidney disease.


Eligibility criteria: Inclusion Criteria:

* Heart failure with New York Heart Association (NYHA) Classification II or III
* Chronic kidney disease
* Cardiac ejection fraction \<40%
* On heart failure therapy including an ACEI or ARB, and a BB
* Willing to understand and comply with study procedures and provide written informed consent.

Exclusion Criteria:

* Hospitalization within 4 weeks of baseline visit
* History or presence of gastrointestinal conditions such as severe constipation or gastrointestinal tract strictures
* Current or anticipated dialysis during study
* In the investigator's judgment, any cardiovascular, renal, hepatic, endocrine, gastrointestinal, neurological, or other disease or condition that makes the subject's study participation unsafe
* Drug or alcohol abuse

Primary outcomes:
measure: Change in Fecal Sodium Content
timeFrame: baseline average (days 3-6 or days 22-25) and treatment average (days 10-13 or 29-32)
Secondary outcomes:
measure: Change in Fecal Weight
timeFrame: baseline average (days 3-6 or 22-25) and treatment average (days 10-13 or 29-32)
Other outcomes:
Locations:
city: Tustin
country: United States
facility: Orange Country Research Center
state: California
Study officials:
affiliation: Sorbent Therapeutics, Study Sponsor
name: Howard Dittrich, MD
role: STUDY_CHAIR
affiliation: Orange County Research Center
name: Joel Neutel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04582240: Bile Duct Injury Digestif
Official title: Full Data BDI Digestif RSCM
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Surgery
Biliary Disease
Bile Duct Injury
Sepsis
Jaundice, Obstructive
Lead sponsor: Dr Cipto Mangunkusumo General Hospital
Sponsor class: OTHER
First posted: 2020-10-09
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients who experienced complication after performed cholecystectomy, open or laparoscopy, related to biliary duct

Brief summary: Data accumulated from medical record collected from January 2008 until December 2018


Eligibility criteria: Inclusion Criteria:

* adult patients with extrahepatic bile duct injury managed by digestive division of Cipto Mangunkusumo hospital

Exclusion Criteria:

* none

Primary outcomes:
measure: Management of Post-Cholecystectomy Bile Duct Injuries without Operative Mortality at Jakarta Tertiary Hospital in Indonesia
timeFrame: january 2008 until december 2018
Secondary outcomes:
measure: Management of Post-Cholecystectomy Bile Duct Injuries without Operative Mortality at Jakarta Tertiary Hospital in Indonesia
timeFrame: january 2008 until december 2018
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05028140: Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
Official title: National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Type II Diabetes
Keywords: Type II diabetes mellitus
Lead sponsor: EMS
Sponsor class: INDUSTRY
First posted: 2021-08-31
Enrollment: 480
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy and safety of Piemonte association in the treatment of type 2 diabetes mellitus


Eligibility criteria: Inclusion Criteria:

* Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the consent form;
* Diagnosis of type II diabetes mellitus, and who did not reach the therapeutic goal of HbA1c with previous dietary, physical exercise, and previous therapies at stable doses within 3 months.

Exclusion Criteria:

* Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of participants;
* History of alcohol abuse or illicit drug use;
* Participation in a clinical trial in the year prior to this study;
* Pregnancy or risk of pregnacy and lactating participants;
* Known hypersensitivity to any of the formula compounds;
* Type 1 diabetes.

Primary outcomes:
measure: Glycated hemoglobin
timeFrame: 120 days
Secondary outcomes:
measure: Adverse events
timeFrame: 150 days
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01099540: Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
Official title: Phase II Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Neuroendocrine Tumor
Keywords: neuroendocrine tumor
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2010-04-07
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To determine the response rate of pazopanib when administered as monotherapy in patients with unresectable neuroendocrine tumor.


Eligibility criteria: Inclusion Criteria:

* low to intermediate grade neuroendocrine tumor not amenable to surgery or local therapy

Exclusion Criteria:

* poorly differentiated (high grade or anaplastic)/small cell, pheochromocytoma

Primary outcomes:
measure: response rate
timeFrame: 1~2 year
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Cancer Center
Study officials:
References:
citation: Ahn HK, Choi JY, Kim KM, Kim H, Choi SH, Park SH, Park JO, Lim HY, Kang WK, Lee J, Park YS. Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours. Br J Cancer. 2013 Sep 17;109(6):1414-9. doi: 10.1038/bjc.2013.470. Epub 2013 Aug 29.
Clinical trial NCT00760240: Ability of Patients With Low Vision to Properly Instill Eye Drops
Official title: Objective Evaluation of the Ability of Patients With Decreased Vision or Restricted Visual Fields to Properly Instill Eye Drops
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Glaucoma
Retinal Pathology
Keywords: compliance
eyedrop instillation
How patients with low vision due to glaucoma or retinal pathology instill eyedrops into their own eyes.
Lead sponsor: Mid-Atlantic Glaucoma Experts
Sponsor class: OTHER
First posted: 2008-09-26
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients reporting for appointments at outpatients referral practices shared by 2 glaucoma and 3 retina specialists

Brief summary: The investigators are interested in seeing how people with low vision (decreased visual acuity or restricted visual fields) instill eye drops into their own eyes. The investigators hypothesis is that this population will have more difficulty with self-instillation of drops than a better-seeing population. The investigators aim to explore whatever factors may be involved in preventing this population from getting prescribed eyedrops into their eyes, whether it is more related to visual field or visual acuity.

Detailed description: This is a study that involves a questionnaire that a study participant fills out, detailing their experience with eyedrops (if any), followed by a video recording of them instilling artificial tears into their worse-seeing eye, with their dominant hand. Patients must have visual acuity worse than 20/60 in at least one eye, and/or have a recent visual field that demonstrated Hodapp criteria for Moderate or Severe visual field damage. This is an observational study of how patients with low vision due to either glaucoma or retinal disease instill eyedrops. Each video will be "graded" by the principal investigator for "success" at instilling eyedrops, and patients will be stratified by their visual acuity or visual field, and whether they have a primary diagnosis of glaucoma or retinal disease.

Eligibility criteria: Inclusion Criteria:

* ETDRS visual acuity 20/60 or worse

Exclusion Criteria:

* Unwilling to participate
* Light perception vision
* No light perception vision

Primary outcomes:
measure: Successful instillation of a single eyedrop onto the surface of the eye
timeFrame: 2 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Glaucoma Specialists/Retina Care Center
state: Maryland
Study officials:
References:
Clinical trial NCT05766644: App-based Education Program for CKD
Official title: Open-label, Randomized Comparative Clinical Trial on the Clinical Effect of App-based Education Program in Patients With Chronic Kidney Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Renal Insufficiency, Chronic
Lead sponsor: Inje University
Sponsor class: OTHER
Collaborators: name: Hallym University Kangnam Sacred Heart Hospital
name: KangWon National University Hospital
name: Korea University Guro Hospital
name: Korea University Ansan Hospital
name: Seoul National University
name: Ministry of Health & Welfare, Korea
First posted: 2023-03-13
Enrollment: 129
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: A randomized control trial to test the effect of a mobile app-based educational program for Chronic Kidney Disease patients.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with CKD Stage 1\~5
* Have been receiving CKD treatment for more than 6 months
* Owns an android mobile phone

Exclusion Criteria:

* Diagnosed with cancer within 5 years of recruitment

Primary outcomes:
measure: Quality of Life (SF-36v2)
timeFrame: 48 days
measure: MIS
timeFrame: 55 days
measure: Potassium
timeFrame: 56 days
measure: Phosphate
timeFrame: 56 days
measure: Albumin
timeFrame: 56 days
Secondary outcomes:
measure: Depression
timeFrame: 55 days
measure: Insomnia
timeFrame: 48 days
measure: Sodium intake behavior
timeFrame: 0 days
measure: Sodium intake attitude
timeFrame: 0 days
measure: Creatinine
timeFrame: 56 days
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Inje University Seoul Paik Hospital
Study officials:
affiliation: Inje University
name: Hoseok Koo
role: PRINCIPAL_INVESTIGATOR
References: